Hikma Pharmaceuticals PLC
United Kingdom · GB00B0LCW083 · reports in USD · Europe
The answers
From the annual report for the year to Dec 31, 2025. Each line says what it is based on.
- Is it growing?Fair
- Revenue +7.1% in the year to Dec 31, 2025, on the year before.
- Is it a good business?Good
- It earned 16% on its shareholders' equity in the year to Dec 31, 2025.
- Is it safe?Fair
- Equity is 46% of its assets, and operations brought in cash in the year.
- Is the price fair?n/a
- Not answered: no exchange publishes this company's price for free reuse, so there is no P/E here.
The year
Year to Dec 31, 2025, consolidated, in USD.
revenue
operating margin
net profit
Year by year
As filed; an earlier year can differ from its own report when the company restated it.
| Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 | |
|---|---|---|---|---|
| Revenue | $2.5B | $2.9B | $3.1B | $3.3B |
| Operating profit | $282M | $367M | $612M | $542M |
| Net profit to shareholders | $188M | $190M | $359M | $402M |
| Earnings per share | $0.84 | $0.86 | $1.62 | $1.82 |
| Cash from operations | $530M | $608M | $564M | $436M |
| Capital spending | $138M | $169M | $165M | $197M |
| Cash | $270M | $205M | $188M | $217M |
| Total assets | $4.5B | $4.7B | $5.1B | $5.7B |
| Equity | $2.1B | $2.2B | $2.3B | $2.6B |
What they do
In the company's own words, from the annual report.
The Group’s principal activities are the development, manufacture and commercialisation of a broad range of generic, specialty and branded pharmaceutical products across a range of dosage forms.
Source: the company’s annual financial report in ESEF, via filings.xbrl.org (XBRL International). Listed shares from ESMA’s FIRDS register; ESMA does not endorse this site. Ryufin computed the answers and ratios from the filed figures.